Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Unverdorben

Showing results (41-50 of 76) with videos related to

Pageof 8
Sort By:
Journal of Clinical Medicine|March 11, 2023
Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation: One-Year Data from the Global ETNA-AF ProgramTze-Fan Chao, Martin Unverdorben, Paulus Kirchhof, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|June 29, 2026
Edoxaban versus Apixaban Outcomes Differences in 8,444 Patients with Atrial Fibrillation from Italy: A Real-World Use ComparisonAngel Valladares, Joseph Imperato, Sidharth Gupta, et al.
Clinical Cardiology|February 27, 2025
Two-Year Follow-Up of Patients With Atrial Fibrillation Receiving Edoxaban in Routine Clinical Practice: Results From the Global ETNA-AF ProgramRaffaele De Caterina, Martin Unverdorben, Cathy Chen, et al.
The Journal of Invasive Cardiology|April 16, 2005
Evaluation of the Coroflex Theca-Stent for reduction of restenosis (ECORI)Martin Unverdorben, Ralf Degenhardt, Peter Sick, et al.
JACC. Advances|February 26, 2026
Bayesian Machine Learning Model Guiding Iterative, Personalized Anticoagulant Dosing Decision-Making: ENGAGE AF-TIMI 48 Trial AnalysisC Michael Gibson, Cathy Chen, Jacqueline Buros-Novik, et al.
European Heart Journal Open|March 31, 2025
Edoxaban treatment in routine clinical practice is highly concordant with the 2020 European Society of Cardiology atrial fibrillation guidelines: results from the noninterventional Global ETNA-AF programmeDoralisa Morrone, Leon Dinshaw, José Antonio Gordillo de Souza, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|January 31, 2024
Outcomes after TAVI in patients with atrial fibrillation and a history of recent PCI: Results from the ENVISAGE-TAVI AF trialRaúl Moreno, José Souza, Rüdiger Smolnik, et al.
JACC. Advances|November 20, 2025
Edoxaban Dose Adjustment and Age-Associated Outcomes in Patients With Atrial Fibrillation Post-Transcatheter Aortic Valve ReplacementNicolas M Van Mieghem, Cathy Chen, Christian Hengstenberg, et al.
American Heart Journal|September 2, 2018
Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation-Rationale and design of the ENVISAGE-TAVI AF trialNicolas M Van Mieghem, Martin Unverdorben, Marco Valgimigli, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|January 7, 2010
Treatment of small coronary arteries with a paclitaxel-coated balloon catheterMartin Unverdorben, Franz X Kleber, Hubertus Heuer, et al.
Pageof 8

Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
Journal of Clinical Medicine|March 11, 2023
Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation: One-Year Data from the Global ETNA-AF ProgramTze-Fan Chao, Martin Unverdorben, Paulus Kirchhof, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|June 29, 2026
Edoxaban versus Apixaban Outcomes Differences in 8,444 Patients with Atrial Fibrillation from Italy: A Real-World Use ComparisonAngel Valladares, Joseph Imperato, Sidharth Gupta, et al.
Clinical Cardiology|February 27, 2025
Two-Year Follow-Up of Patients With Atrial Fibrillation Receiving Edoxaban in Routine Clinical Practice: Results From the Global ETNA-AF ProgramRaffaele De Caterina, Martin Unverdorben, Cathy Chen, et al.
The Journal of Invasive Cardiology|April 16, 2005
Evaluation of the Coroflex Theca-Stent for reduction of restenosis (ECORI)Martin Unverdorben, Ralf Degenhardt, Peter Sick, et al.
JACC. Advances|February 26, 2026
Bayesian Machine Learning Model Guiding Iterative, Personalized Anticoagulant Dosing Decision-Making: ENGAGE AF-TIMI 48 Trial AnalysisC Michael Gibson, Cathy Chen, Jacqueline Buros-Novik, et al.
European Heart Journal Open|March 31, 2025
Edoxaban treatment in routine clinical practice is highly concordant with the 2020 European Society of Cardiology atrial fibrillation guidelines: results from the noninterventional Global ETNA-AF programmeDoralisa Morrone, Leon Dinshaw, José Antonio Gordillo de Souza, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|January 31, 2024
Outcomes after TAVI in patients with atrial fibrillation and a history of recent PCI: Results from the ENVISAGE-TAVI AF trialRaúl Moreno, José Souza, Rüdiger Smolnik, et al.
JACC. Advances|November 20, 2025
Edoxaban Dose Adjustment and Age-Associated Outcomes in Patients With Atrial Fibrillation Post-Transcatheter Aortic Valve ReplacementNicolas M Van Mieghem, Cathy Chen, Christian Hengstenberg, et al.
American Heart Journal|September 2, 2018
Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation-Rationale and design of the ENVISAGE-TAVI AF trialNicolas M Van Mieghem, Martin Unverdorben, Marco Valgimigli, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|January 7, 2010
Treatment of small coronary arteries with a paclitaxel-coated balloon catheterMartin Unverdorben, Franz X Kleber, Hubertus Heuer, et al.
Pageof 8